{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.0","value":"46.3"}]}],"title":"Cmin Dose 3 (n=248)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.0","value":"65.1"}]}],"title":"Cmin Dose 5 (n=154)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.0","value":"77.9"}]}],"title":"Cmin Dose 9 (n=27)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.0","value":"75.9"}]}],"title":"Cmin Dose 13 (n=11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.0","value":"72.0"}]}],"title":"Cmin Dose 17 (n=5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.0","value":"221.0"}]}],"title":"Cmax Dose 3 (n=88)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.0","value":"243.0"}]}],"title":"Cmax Dose 5 (n=51)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.0","value":"262.0"}]}],"title":"Cmax Dose 9 (n=18)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.0","value":"307.0"}]}],"title":"Cmax Dose 13 (n=12)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.0","value":"253.0"}]}],"title":"Cmax Dose 17 (n=7)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"On Day 1 of each 14-day cycle, participants received ramucirumab followed by other study treatment in the following sequence: Irinotecan, Folinic Acid and 5-Fluorouracil. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\nRamucirumab: 8 mg/kg administered intravenously.\n\nIrinotecan: 180 mg/m\\^2 administered intravenously.\n\nFolinic Acid: 400 mg/m\\^2 administered intravenously.\n\n5-Fluorouracil: 400 mg/m\\^2 bolus immediately followed by 2400 mg/m\\^2 continuous infusion.","id":"OG000","title":"Ramucirumab + FOLFIRI"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable data for Cmin and Cmax.","reportingStatus":"POSTED","timeFrame":"Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17","title":"Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab","type":"SECONDARY","unitOfMeasure":"micrograms/milliliter (ug/mL)"}